nodes	percent_of_prediction	percent_of_DWPC	metapath
Bicalutamide—AR—Medroxyprogesterone Acetate—uterine cancer	0.322	0.425	CbGbCtD
Bicalutamide—AR—Progesterone—uterine cancer	0.213	0.282	CbGbCtD
Bicalutamide—CYP2C9—Medroxyprogesterone Acetate—uterine cancer	0.0492	0.0649	CbGbCtD
Bicalutamide—CYP2C19—Progesterone—uterine cancer	0.0392	0.0517	CbGbCtD
Bicalutamide—CYP2C9—Progesterone—uterine cancer	0.0326	0.043	CbGbCtD
Bicalutamide—CYP2D6—Progesterone—uterine cancer	0.0298	0.0393	CbGbCtD
Bicalutamide—CYP3A4—Medroxyprogesterone Acetate—uterine cancer	0.0286	0.0378	CbGbCtD
Bicalutamide—CYP3A4—Progesterone—uterine cancer	0.0189	0.025	CbGbCtD
Bicalutamide—CYP2D6—Doxorubicin—uterine cancer	0.00909	0.012	CbGbCtD
Bicalutamide—CYP3A4—Etoposide—uterine cancer	0.00847	0.0112	CbGbCtD
Bicalutamide—CYP3A4—Doxorubicin—uterine cancer	0.00578	0.00763	CbGbCtD
Bicalutamide—AR—semen—uterine cancer	0.00495	0.227	CbGeAlD
Bicalutamide—AR—oviduct—uterine cancer	0.00363	0.166	CbGeAlD
Bicalutamide—AR—myometrium—uterine cancer	0.00116	0.0532	CbGeAlD
Bicalutamide—AR—epithelium—uterine cancer	0.000911	0.0417	CbGeAlD
Bicalutamide—AR—uterine cervix—uterine cancer	0.000903	0.0414	CbGeAlD
Bicalutamide—AR—smooth muscle tissue—uterine cancer	0.000878	0.0402	CbGeAlD
Bicalutamide—AR—decidua—uterine cancer	0.00086	0.0394	CbGeAlD
Bicalutamide—AR—renal system—uterine cancer	0.000845	0.0387	CbGeAlD
Bicalutamide—AR—endometrium—uterine cancer	0.000817	0.0374	CbGeAlD
Bicalutamide—AR—mammalian vulva—uterine cancer	0.00079	0.0362	CbGeAlD
Bicalutamide—AR—uterus—uterine cancer	0.000753	0.0345	CbGeAlD
Bicalutamide—AR—female reproductive system—uterine cancer	0.000677	0.031	CbGeAlD
Bicalutamide—AR—female gonad—uterine cancer	0.000616	0.0282	CbGeAlD
Bicalutamide—AR—vagina—uterine cancer	0.000612	0.028	CbGeAlD
Bicalutamide—AR—Coregulation of Androgen receptor activity—PAWR—uterine cancer	0.000594	0.0533	CbGpPWpGaD
Bicalutamide—CYP2C19—vagina—uterine cancer	0.000567	0.026	CbGeAlD
Bicalutamide—CYP2C9—female reproductive system—uterine cancer	0.000486	0.0223	CbGeAlD
Bicalutamide—CYP3A4—renal system—uterine cancer	0.000463	0.0212	CbGeAlD
Bicalutamide—CYP2D6—renal system—uterine cancer	0.000455	0.0209	CbGeAlD
Bicalutamide—AR—lymph node—uterine cancer	0.000396	0.0181	CbGeAlD
Bicalutamide—CYP3A4—female reproductive system—uterine cancer	0.000371	0.017	CbGeAlD
Bicalutamide—CYP2D6—female reproductive system—uterine cancer	0.000365	0.0167	CbGeAlD
Bicalutamide—CYP2D6—female gonad—uterine cancer	0.000332	0.0152	CbGeAlD
Bicalutamide—CYP3A4—Benzo(a)pyrene metabolism—AKR1C1—uterine cancer	0.000326	0.0293	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—PGR—uterine cancer	0.000308	0.0276	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptors—ESR2—uterine cancer	0.000271	0.0243	CbGpPWpGaD
Bicalutamide—CYP3A4—Benzo(a)pyrene metabolism—AKR1C3—uterine cancer	0.000251	0.0225	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—PGR—uterine cancer	0.000243	0.0218	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000224	0.0201	CbGpPWpGaD
Bicalutamide—AR—Nuclear Receptor transcription pathway—ESR2—uterine cancer	0.000214	0.0192	CbGpPWpGaD
Bicalutamide—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000176	0.000837	CcSEcCtD
Bicalutamide—Headache—Medroxyprogesterone Acetate—uterine cancer	0.000175	0.000833	CcSEcCtD
Bicalutamide—Face oedema—Epirubicin—uterine cancer	0.000173	0.000826	CcSEcCtD
Bicalutamide—Body temperature increased—Dactinomycin—uterine cancer	0.000172	0.00082	CcSEcCtD
Bicalutamide—Abdominal pain—Dactinomycin—uterine cancer	0.000172	0.00082	CcSEcCtD
Bicalutamide—Cardiac arrest—Epirubicin—uterine cancer	0.000171	0.000814	CcSEcCtD
Bicalutamide—Cardiac failure—Doxorubicin—uterine cancer	0.00017	0.000811	CcSEcCtD
Bicalutamide—Hypoglycaemia—Doxorubicin—uterine cancer	0.00017	0.000811	CcSEcCtD
Bicalutamide—Loss of consciousness—Etoposide—uterine cancer	0.00017	0.000808	CcSEcCtD
Bicalutamide—Cerebrovascular accident—Doxorubicin—uterine cancer	0.00017	0.000808	CcSEcCtD
Bicalutamide—Cough—Etoposide—uterine cancer	0.000168	0.000802	CcSEcCtD
Bicalutamide—Blood creatinine increased—Epirubicin—uterine cancer	0.000168	0.000802	CcSEcCtD
Bicalutamide—Dehydration—Epirubicin—uterine cancer	0.000167	0.000796	CcSEcCtD
Bicalutamide—Hypertension—Etoposide—uterine cancer	0.000167	0.000794	CcSEcCtD
Bicalutamide—Liver function test abnormal—Epirubicin—uterine cancer	0.000166	0.00079	CcSEcCtD
Bicalutamide—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000166	0.000789	CcSEcCtD
Bicalutamide—Dry skin—Epirubicin—uterine cancer	0.000165	0.000784	CcSEcCtD
Bicalutamide—AR—Nuclear Receptors—ESR1—uterine cancer	0.000164	0.0147	CbGpPWpGaD
Bicalutamide—Chest pain—Etoposide—uterine cancer	0.000164	0.000783	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000163	0.000777	CcSEcCtD
Bicalutamide—Breast disorder—Epirubicin—uterine cancer	0.000162	0.000773	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—YWHAE—uterine cancer	0.000162	0.0145	CbGpPWpGaD
Bicalutamide—Aspartate aminotransferase increased—Epirubicin—uterine cancer	0.000162	0.000771	CcSEcCtD
Bicalutamide—Face oedema—Doxorubicin—uterine cancer	0.00016	0.000764	CcSEcCtD
Bicalutamide—Hypersensitivity—Dactinomycin—uterine cancer	0.00016	0.000764	CcSEcCtD
Bicalutamide—Gastritis—Epirubicin—uterine cancer	0.000159	0.000757	CcSEcCtD
Bicalutamide—Confusional state—Etoposide—uterine cancer	0.000159	0.000757	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Epirubicin—uterine cancer	0.000158	0.000755	CcSEcCtD
Bicalutamide—Muscular weakness—Epirubicin—uterine cancer	0.000158	0.000755	CcSEcCtD
Bicalutamide—Cardiac arrest—Doxorubicin—uterine cancer	0.000158	0.000753	CcSEcCtD
Bicalutamide—Infection—Etoposide—uterine cancer	0.000156	0.000745	CcSEcCtD
Bicalutamide—Asthenia—Dactinomycin—uterine cancer	0.000156	0.000744	CcSEcCtD
Bicalutamide—Blood creatinine increased—Doxorubicin—uterine cancer	0.000156	0.000742	CcSEcCtD
Bicalutamide—Influenza—Epirubicin—uterine cancer	0.000155	0.00074	CcSEcCtD
Bicalutamide—Asthma—Epirubicin—uterine cancer	0.000155	0.00074	CcSEcCtD
Bicalutamide—Dysphagia—Epirubicin—uterine cancer	0.000155	0.00074	CcSEcCtD
Bicalutamide—Dehydration—Doxorubicin—uterine cancer	0.000155	0.000736	CcSEcCtD
Bicalutamide—Thrombocytopenia—Etoposide—uterine cancer	0.000154	0.000735	CcSEcCtD
Bicalutamide—Eosinophilia—Epirubicin—uterine cancer	0.000154	0.000732	CcSEcCtD
Bicalutamide—Liver function test abnormal—Doxorubicin—uterine cancer	0.000153	0.000731	CcSEcCtD
Bicalutamide—Skin disorder—Etoposide—uterine cancer	0.000153	0.000729	CcSEcCtD
Bicalutamide—Dry skin—Doxorubicin—uterine cancer	0.000152	0.000726	CcSEcCtD
Bicalutamide—Hyperhidrosis—Etoposide—uterine cancer	0.000152	0.000725	CcSEcCtD
Bicalutamide—Angina pectoris—Epirubicin—uterine cancer	0.000151	0.00072	CcSEcCtD
Bicalutamide—Breast disorder—Doxorubicin—uterine cancer	0.00015	0.000716	CcSEcCtD
Bicalutamide—Anorexia—Etoposide—uterine cancer	0.00015	0.000715	CcSEcCtD
Bicalutamide—Aspartate aminotransferase increased—Doxorubicin—uterine cancer	0.00015	0.000713	CcSEcCtD
Bicalutamide—Bronchitis—Epirubicin—uterine cancer	0.000149	0.000711	CcSEcCtD
Bicalutamide—Diarrhoea—Dactinomycin—uterine cancer	0.000149	0.000709	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MSH6—uterine cancer	0.000147	0.0132	CbGpPWpGaD
Bicalutamide—Gastritis—Doxorubicin—uterine cancer	0.000147	0.000701	CcSEcCtD
Bicalutamide—Muscular weakness—Doxorubicin—uterine cancer	0.000147	0.000698	CcSEcCtD
Bicalutamide—Alanine aminotransferase increased—Doxorubicin—uterine cancer	0.000147	0.000698	CcSEcCtD
Bicalutamide—AR—FOXA1 transcription factor network—ESR1—uterine cancer	0.000146	0.0131	CbGpPWpGaD
Bicalutamide—Dysuria—Epirubicin—uterine cancer	0.000145	0.000692	CcSEcCtD
Bicalutamide—Neutropenia—Epirubicin—uterine cancer	0.000145	0.000692	CcSEcCtD
Bicalutamide—Dysphagia—Doxorubicin—uterine cancer	0.000144	0.000684	CcSEcCtD
Bicalutamide—Asthma—Doxorubicin—uterine cancer	0.000144	0.000684	CcSEcCtD
Bicalutamide—Influenza—Doxorubicin—uterine cancer	0.000144	0.000684	CcSEcCtD
Bicalutamide—Pollakiuria—Epirubicin—uterine cancer	0.000143	0.000683	CcSEcCtD
Bicalutamide—Eosinophilia—Doxorubicin—uterine cancer	0.000142	0.000678	CcSEcCtD
Bicalutamide—Paraesthesia—Etoposide—uterine cancer	0.000141	0.000674	CcSEcCtD
Bicalutamide—Weight increased—Epirubicin—uterine cancer	0.000141	0.000673	CcSEcCtD
Bicalutamide—Weight decreased—Epirubicin—uterine cancer	0.00014	0.000669	CcSEcCtD
Bicalutamide—Dyspnoea—Etoposide—uterine cancer	0.00014	0.000669	CcSEcCtD
Bicalutamide—Hyperglycaemia—Epirubicin—uterine cancer	0.00014	0.000667	CcSEcCtD
Bicalutamide—Somnolence—Etoposide—uterine cancer	0.00014	0.000667	CcSEcCtD
Bicalutamide—Angina pectoris—Doxorubicin—uterine cancer	0.00014	0.000667	CcSEcCtD
Bicalutamide—Pneumonia—Epirubicin—uterine cancer	0.000139	0.000663	CcSEcCtD
Bicalutamide—Vomiting—Dactinomycin—uterine cancer	0.000138	0.000659	CcSEcCtD
Bicalutamide—Bronchitis—Doxorubicin—uterine cancer	0.000138	0.000658	CcSEcCtD
Bicalutamide—Rash—Dactinomycin—uterine cancer	0.000137	0.000654	CcSEcCtD
Bicalutamide—Decreased appetite—Etoposide—uterine cancer	0.000137	0.000652	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Etoposide—uterine cancer	0.000136	0.000648	CcSEcCtD
Bicalutamide—Fatigue—Etoposide—uterine cancer	0.000136	0.000647	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Epirubicin—uterine cancer	0.000136	0.000646	CcSEcCtD
Bicalutamide—Jaundice—Epirubicin—uterine cancer	0.000135	0.000643	CcSEcCtD
Bicalutamide—Constipation—Etoposide—uterine cancer	0.000135	0.000642	CcSEcCtD
Bicalutamide—Pain—Etoposide—uterine cancer	0.000135	0.000642	CcSEcCtD
Bicalutamide—Conjunctivitis—Epirubicin—uterine cancer	0.000135	0.000641	CcSEcCtD
Bicalutamide—Urinary tract infection—Epirubicin—uterine cancer	0.000135	0.000641	CcSEcCtD
Bicalutamide—Dysuria—Doxorubicin—uterine cancer	0.000134	0.00064	CcSEcCtD
Bicalutamide—Neutropenia—Doxorubicin—uterine cancer	0.000134	0.00064	CcSEcCtD
Bicalutamide—Sweating—Epirubicin—uterine cancer	0.000133	0.000632	CcSEcCtD
Bicalutamide—Pollakiuria—Doxorubicin—uterine cancer	0.000133	0.000632	CcSEcCtD
Bicalutamide—Haematuria—Epirubicin—uterine cancer	0.000132	0.000629	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Epirubicin—uterine cancer	0.000131	0.000624	CcSEcCtD
Bicalutamide—Weight increased—Doxorubicin—uterine cancer	0.000131	0.000623	CcSEcCtD
Bicalutamide—Epistaxis—Epirubicin—uterine cancer	0.000131	0.000622	CcSEcCtD
Bicalutamide—Weight decreased—Doxorubicin—uterine cancer	0.00013	0.000619	CcSEcCtD
Bicalutamide—AR—Nuclear Receptor transcription pathway—ESR1—uterine cancer	0.00013	0.0117	CbGpPWpGaD
Bicalutamide—Sinusitis—Epirubicin—uterine cancer	0.00013	0.000619	CcSEcCtD
Bicalutamide—Feeling abnormal—Etoposide—uterine cancer	0.00013	0.000618	CcSEcCtD
Bicalutamide—Hyperglycaemia—Doxorubicin—uterine cancer	0.00013	0.000617	CcSEcCtD
Bicalutamide—Nausea—Dactinomycin—uterine cancer	0.000129	0.000616	CcSEcCtD
Bicalutamide—Pneumonia—Doxorubicin—uterine cancer	0.000129	0.000614	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Etoposide—uterine cancer	0.000129	0.000614	CcSEcCtD
Bicalutamide—Bradycardia—Epirubicin—uterine cancer	0.000127	0.000603	CcSEcCtD
Bicalutamide—Neuropathy peripheral—Doxorubicin—uterine cancer	0.000126	0.000598	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	0.000125	0.0112	CbGpPWpGaD
Bicalutamide—Urticaria—Etoposide—uterine cancer	0.000125	0.000596	CcSEcCtD
Bicalutamide—Haemoglobin—Epirubicin—uterine cancer	0.000125	0.000595	CcSEcCtD
Bicalutamide—Jaundice—Doxorubicin—uterine cancer	0.000125	0.000595	CcSEcCtD
Bicalutamide—Rhinitis—Epirubicin—uterine cancer	0.000125	0.000593	CcSEcCtD
Bicalutamide—Body temperature increased—Etoposide—uterine cancer	0.000125	0.000593	CcSEcCtD
Bicalutamide—Abdominal pain—Etoposide—uterine cancer	0.000125	0.000593	CcSEcCtD
Bicalutamide—Urinary tract infection—Doxorubicin—uterine cancer	0.000125	0.000593	CcSEcCtD
Bicalutamide—Conjunctivitis—Doxorubicin—uterine cancer	0.000125	0.000593	CcSEcCtD
Bicalutamide—Haemorrhage—Epirubicin—uterine cancer	0.000124	0.000592	CcSEcCtD
Bicalutamide—Pharyngitis—Epirubicin—uterine cancer	0.000123	0.000588	CcSEcCtD
Bicalutamide—Sweating—Doxorubicin—uterine cancer	0.000123	0.000585	CcSEcCtD
Bicalutamide—Urinary tract disorder—Epirubicin—uterine cancer	0.000123	0.000585	CcSEcCtD
Bicalutamide—Oedema peripheral—Epirubicin—uterine cancer	0.000122	0.000583	CcSEcCtD
Bicalutamide—Haematuria—Doxorubicin—uterine cancer	0.000122	0.000582	CcSEcCtD
Bicalutamide—Urethral disorder—Epirubicin—uterine cancer	0.000122	0.00058	CcSEcCtD
Bicalutamide—Hepatobiliary disease—Doxorubicin—uterine cancer	0.000121	0.000577	CcSEcCtD
Bicalutamide—Epistaxis—Doxorubicin—uterine cancer	0.000121	0.000576	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—CDKN2B—uterine cancer	0.00012	0.0108	CbGpPWpGaD
Bicalutamide—Sinusitis—Doxorubicin—uterine cancer	0.00012	0.000572	CcSEcCtD
Bicalutamide—Visual impairment—Epirubicin—uterine cancer	0.00012	0.00057	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—MSH2—uterine cancer	0.000119	0.0107	CbGpPWpGaD
Bicalutamide—Bradycardia—Doxorubicin—uterine cancer	0.000117	0.000558	CcSEcCtD
Bicalutamide—Hypersensitivity—Etoposide—uterine cancer	0.000116	0.000553	CcSEcCtD
Bicalutamide—Haemoglobin—Doxorubicin—uterine cancer	0.000116	0.000551	CcSEcCtD
Bicalutamide—Cardiac disorder—Epirubicin—uterine cancer	0.000115	0.000549	CcSEcCtD
Bicalutamide—Rhinitis—Doxorubicin—uterine cancer	0.000115	0.000549	CcSEcCtD
Bicalutamide—Haemorrhage—Doxorubicin—uterine cancer	0.000115	0.000548	CcSEcCtD
Bicalutamide—Pharyngitis—Doxorubicin—uterine cancer	0.000114	0.000544	CcSEcCtD
Bicalutamide—Urinary tract disorder—Doxorubicin—uterine cancer	0.000114	0.000541	CcSEcCtD
Bicalutamide—Oedema peripheral—Doxorubicin—uterine cancer	0.000113	0.00054	CcSEcCtD
Bicalutamide—Asthenia—Etoposide—uterine cancer	0.000113	0.000538	CcSEcCtD
Bicalutamide—Angiopathy—Epirubicin—uterine cancer	0.000113	0.000537	CcSEcCtD
Bicalutamide—Urethral disorder—Doxorubicin—uterine cancer	0.000113	0.000537	CcSEcCtD
Bicalutamide—Immune system disorder—Epirubicin—uterine cancer	0.000112	0.000535	CcSEcCtD
Bicalutamide—Mediastinal disorder—Epirubicin—uterine cancer	0.000112	0.000534	CcSEcCtD
Bicalutamide—Chills—Epirubicin—uterine cancer	0.000112	0.000531	CcSEcCtD
Bicalutamide—Pruritus—Etoposide—uterine cancer	0.000111	0.000531	CcSEcCtD
Bicalutamide—Arrhythmia—Epirubicin—uterine cancer	0.000111	0.000529	CcSEcCtD
Bicalutamide—Visual impairment—Doxorubicin—uterine cancer	0.000111	0.000528	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—SMAD3—uterine cancer	0.00011	0.00986	CbGpPWpGaD
Bicalutamide—Alopecia—Epirubicin—uterine cancer	0.00011	0.000523	CcSEcCtD
Bicalutamide—Mental disorder—Epirubicin—uterine cancer	0.000109	0.000519	CcSEcCtD
Bicalutamide—Malnutrition—Epirubicin—uterine cancer	0.000108	0.000515	CcSEcCtD
Bicalutamide—Diarrhoea—Etoposide—uterine cancer	0.000108	0.000513	CcSEcCtD
Bicalutamide—Cardiac disorder—Doxorubicin—uterine cancer	0.000107	0.000508	CcSEcCtD
Bicalutamide—Flatulence—Epirubicin—uterine cancer	0.000107	0.000508	CcSEcCtD
Bicalutamide—Tension—Epirubicin—uterine cancer	0.000106	0.000506	CcSEcCtD
Bicalutamide—CYP2C19—Arachidonic acid metabolism—AKR1C3—uterine cancer	0.000106	0.0095	CbGpPWpGaD
Bicalutamide—Nervousness—Epirubicin—uterine cancer	0.000105	0.000501	CcSEcCtD
Bicalutamide—Back pain—Epirubicin—uterine cancer	0.000105	0.000498	CcSEcCtD
Bicalutamide—Angiopathy—Doxorubicin—uterine cancer	0.000104	0.000497	CcSEcCtD
Bicalutamide—Dizziness—Etoposide—uterine cancer	0.000104	0.000496	CcSEcCtD
Bicalutamide—Muscle spasms—Epirubicin—uterine cancer	0.000104	0.000495	CcSEcCtD
Bicalutamide—Immune system disorder—Doxorubicin—uterine cancer	0.000104	0.000495	CcSEcCtD
Bicalutamide—Mediastinal disorder—Doxorubicin—uterine cancer	0.000104	0.000494	CcSEcCtD
Bicalutamide—Chills—Doxorubicin—uterine cancer	0.000103	0.000491	CcSEcCtD
Bicalutamide—Arrhythmia—Doxorubicin—uterine cancer	0.000103	0.000489	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—SMAD3—uterine cancer	0.000102	0.00915	CbGpPWpGaD
Bicalutamide—Alopecia—Doxorubicin—uterine cancer	0.000102	0.000484	CcSEcCtD
Bicalutamide—Mental disorder—Doxorubicin—uterine cancer	0.000101	0.00048	CcSEcCtD
Bicalutamide—Vomiting—Etoposide—uterine cancer	0.0001	0.000477	CcSEcCtD
Bicalutamide—Malnutrition—Doxorubicin—uterine cancer	0.0001	0.000477	CcSEcCtD
Bicalutamide—Anaemia—Epirubicin—uterine cancer	0.0001	0.000476	CcSEcCtD
Bicalutamide—AR—FOXA1 transcription factor network—CDKN1B—uterine cancer	9.94e-05	0.00891	CbGpPWpGaD
Bicalutamide—Rash—Etoposide—uterine cancer	9.93e-05	0.000473	CcSEcCtD
Bicalutamide—Dermatitis—Etoposide—uterine cancer	9.92e-05	0.000473	CcSEcCtD
Bicalutamide—Headache—Etoposide—uterine cancer	9.87e-05	0.00047	CcSEcCtD
Bicalutamide—Flatulence—Doxorubicin—uterine cancer	9.86e-05	0.00047	CcSEcCtD
Bicalutamide—Tension—Doxorubicin—uterine cancer	9.82e-05	0.000468	CcSEcCtD
Bicalutamide—Nervousness—Doxorubicin—uterine cancer	9.72e-05	0.000463	CcSEcCtD
Bicalutamide—Syncope—Epirubicin—uterine cancer	9.7e-05	0.000462	CcSEcCtD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	9.69e-05	0.0087	CbGpPWpGaD
Bicalutamide—Back pain—Doxorubicin—uterine cancer	9.68e-05	0.000461	CcSEcCtD
Bicalutamide—CYP2C9—Arachidonic acid metabolism—AKR1C3—uterine cancer	9.66e-05	0.00866	CbGpPWpGaD
Bicalutamide—Muscle spasms—Doxorubicin—uterine cancer	9.62e-05	0.000458	CcSEcCtD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	9.57e-05	0.00858	CbGpPWpGaD
Bicalutamide—Loss of consciousness—Epirubicin—uterine cancer	9.51e-05	0.000453	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—YWHAE—uterine cancer	9.49e-05	0.00851	CbGpPWpGaD
Bicalutamide—Cough—Epirubicin—uterine cancer	9.44e-05	0.00045	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—CDKN1B—uterine cancer	9.43e-05	0.00846	CbGpPWpGaD
Bicalutamide—Nausea—Etoposide—uterine cancer	9.36e-05	0.000446	CcSEcCtD
Bicalutamide—Hypertension—Epirubicin—uterine cancer	9.34e-05	0.000445	CcSEcCtD
Bicalutamide—Anaemia—Doxorubicin—uterine cancer	9.25e-05	0.000441	CcSEcCtD
Bicalutamide—Myalgia—Epirubicin—uterine cancer	9.21e-05	0.000439	CcSEcCtD
Bicalutamide—Chest pain—Epirubicin—uterine cancer	9.21e-05	0.000439	CcSEcCtD
Bicalutamide—Anxiety—Epirubicin—uterine cancer	9.18e-05	0.000437	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	9.15e-05	0.000436	CcSEcCtD
Bicalutamide—Dry mouth—Epirubicin—uterine cancer	9.01e-05	0.000429	CcSEcCtD
Bicalutamide—Syncope—Doxorubicin—uterine cancer	8.98e-05	0.000428	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—ESR1—uterine cancer	8.97e-05	0.00805	CbGpPWpGaD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	8.91e-05	0.008	CbGpPWpGaD
Bicalutamide—Confusional state—Epirubicin—uterine cancer	8.9e-05	0.000424	CcSEcCtD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	8.84e-05	0.00793	CbGpPWpGaD
Bicalutamide—Oedema—Epirubicin—uterine cancer	8.83e-05	0.000421	CcSEcCtD
Bicalutamide—Loss of consciousness—Doxorubicin—uterine cancer	8.8e-05	0.000419	CcSEcCtD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	8.8e-05	0.00789	CbGpPWpGaD
Bicalutamide—Infection—Epirubicin—uterine cancer	8.77e-05	0.000418	CcSEcCtD
Bicalutamide—AR—SIDS Susceptibility Pathways—ESR2—uterine cancer	8.76e-05	0.00786	CbGpPWpGaD
Bicalutamide—Cough—Doxorubicin—uterine cancer	8.73e-05	0.000416	CcSEcCtD
Bicalutamide—AR—FOXA1 transcription factor network—EP300—uterine cancer	8.73e-05	0.00783	CbGpPWpGaD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	8.72e-05	0.00782	CbGpPWpGaD
Bicalutamide—Shock—Epirubicin—uterine cancer	8.69e-05	0.000414	CcSEcCtD
Bicalutamide—Nervous system disorder—Epirubicin—uterine cancer	8.66e-05	0.000412	CcSEcCtD
Bicalutamide—Thrombocytopenia—Epirubicin—uterine cancer	8.64e-05	0.000412	CcSEcCtD
Bicalutamide—Hypertension—Doxorubicin—uterine cancer	8.64e-05	0.000412	CcSEcCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CDKN2A—uterine cancer	8.64e-05	0.00775	CbGpPWpGaD
Bicalutamide—Skin disorder—Epirubicin—uterine cancer	8.58e-05	0.000409	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—PIK3CA—uterine cancer	8.54e-05	0.00766	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Epirubicin—uterine cancer	8.54e-05	0.000407	CcSEcCtD
Bicalutamide—Chest pain—Doxorubicin—uterine cancer	8.52e-05	0.000406	CcSEcCtD
Bicalutamide—Myalgia—Doxorubicin—uterine cancer	8.52e-05	0.000406	CcSEcCtD
Bicalutamide—Anxiety—Doxorubicin—uterine cancer	8.49e-05	0.000405	CcSEcCtD
Bicalutamide—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	8.46e-05	0.000403	CcSEcCtD
Bicalutamide—Anorexia—Epirubicin—uterine cancer	8.42e-05	0.000401	CcSEcCtD
Bicalutamide—Dry mouth—Doxorubicin—uterine cancer	8.33e-05	0.000397	CcSEcCtD
Bicalutamide—AR—Notch-mediated HES/HEY network—EP300—uterine cancer	8.28e-05	0.00743	CbGpPWpGaD
Bicalutamide—Confusional state—Doxorubicin—uterine cancer	8.24e-05	0.000392	CcSEcCtD
Bicalutamide—Oedema—Doxorubicin—uterine cancer	8.17e-05	0.000389	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—STK11—uterine cancer	8.16e-05	0.00732	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CYP19A1—uterine cancer	8.16e-05	0.00732	CbGpPWpGaD
Bicalutamide—Infection—Doxorubicin—uterine cancer	8.12e-05	0.000387	CcSEcCtD
Bicalutamide—Musculoskeletal discomfort—Epirubicin—uterine cancer	8.04e-05	0.000383	CcSEcCtD
Bicalutamide—Shock—Doxorubicin—uterine cancer	8.04e-05	0.000383	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	8.03e-05	0.00721	CbGpPWpGaD
Bicalutamide—Nervous system disorder—Doxorubicin—uterine cancer	8.01e-05	0.000382	CcSEcCtD
Bicalutamide—Thrombocytopenia—Doxorubicin—uterine cancer	8e-05	0.000381	CcSEcCtD
Bicalutamide—Insomnia—Epirubicin—uterine cancer	7.99e-05	0.00038	CcSEcCtD
Bicalutamide—Skin disorder—Doxorubicin—uterine cancer	7.94e-05	0.000378	CcSEcCtD
Bicalutamide—Paraesthesia—Epirubicin—uterine cancer	7.93e-05	0.000378	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—HRAS—uterine cancer	7.9e-05	0.00709	CbGpPWpGaD
Bicalutamide—Hyperhidrosis—Doxorubicin—uterine cancer	7.9e-05	0.000376	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDH1—uterine cancer	7.88e-05	0.00707	CbGpPWpGaD
Bicalutamide—Dyspnoea—Epirubicin—uterine cancer	7.87e-05	0.000375	CcSEcCtD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.86e-05	0.00705	CbGpPWpGaD
Bicalutamide—Somnolence—Epirubicin—uterine cancer	7.85e-05	0.000374	CcSEcCtD
Bicalutamide—Anorexia—Doxorubicin—uterine cancer	7.79e-05	0.000371	CcSEcCtD
Bicalutamide—Dyspepsia—Epirubicin—uterine cancer	7.77e-05	0.00037	CcSEcCtD
Bicalutamide—Decreased appetite—Epirubicin—uterine cancer	7.68e-05	0.000366	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Epirubicin—uterine cancer	7.62e-05	0.000363	CcSEcCtD
Bicalutamide—Fatigue—Epirubicin—uterine cancer	7.61e-05	0.000363	CcSEcCtD
Bicalutamide—Constipation—Epirubicin—uterine cancer	7.55e-05	0.00036	CcSEcCtD
Bicalutamide—Pain—Epirubicin—uterine cancer	7.55e-05	0.00036	CcSEcCtD
Bicalutamide—AR—Regulation of Androgen receptor activity—EP300—uterine cancer	7.52e-05	0.00674	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	7.45e-05	0.00668	CbGpPWpGaD
Bicalutamide—Musculoskeletal discomfort—Doxorubicin—uterine cancer	7.44e-05	0.000355	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—AKR1B10—uterine cancer	7.4e-05	0.00664	CbGpPWpGaD
Bicalutamide—Insomnia—Doxorubicin—uterine cancer	7.39e-05	0.000352	CcSEcCtD
Bicalutamide—Paraesthesia—Doxorubicin—uterine cancer	7.34e-05	0.000349	CcSEcCtD
Bicalutamide—Dyspnoea—Doxorubicin—uterine cancer	7.28e-05	0.000347	CcSEcCtD
Bicalutamide—Feeling abnormal—Epirubicin—uterine cancer	7.28e-05	0.000347	CcSEcCtD
Bicalutamide—Somnolence—Doxorubicin—uterine cancer	7.26e-05	0.000346	CcSEcCtD
Bicalutamide—AR—Coregulation of Androgen receptor activity—CTNNB1—uterine cancer	7.23e-05	0.00648	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.23e-05	0.00648	CbGpPWpGaD
Bicalutamide—Gastrointestinal pain—Epirubicin—uterine cancer	7.22e-05	0.000344	CcSEcCtD
Bicalutamide—Dyspepsia—Doxorubicin—uterine cancer	7.19e-05	0.000343	CcSEcCtD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	7.16e-05	0.00643	CbGpPWpGaD
Bicalutamide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	7.13e-05	0.0064	CbGpPWpGaD
Bicalutamide—Decreased appetite—Doxorubicin—uterine cancer	7.1e-05	0.000338	CcSEcCtD
Bicalutamide—Gastrointestinal disorder—Doxorubicin—uterine cancer	7.05e-05	0.000336	CcSEcCtD
Bicalutamide—Fatigue—Doxorubicin—uterine cancer	7.04e-05	0.000336	CcSEcCtD
Bicalutamide—CYP2C19—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	7.04e-05	0.00631	CbGpPWpGaD
Bicalutamide—Urticaria—Epirubicin—uterine cancer	7.01e-05	0.000334	CcSEcCtD
Bicalutamide—Pain—Doxorubicin—uterine cancer	6.99e-05	0.000333	CcSEcCtD
Bicalutamide—Constipation—Doxorubicin—uterine cancer	6.99e-05	0.000333	CcSEcCtD
Bicalutamide—Abdominal pain—Epirubicin—uterine cancer	6.98e-05	0.000332	CcSEcCtD
Bicalutamide—Body temperature increased—Epirubicin—uterine cancer	6.98e-05	0.000332	CcSEcCtD
Bicalutamide—AR—Nongenotropic Androgen signaling—AKT1—uterine cancer	6.98e-05	0.00626	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CDKN2A—uterine cancer	6.95e-05	0.00624	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—AKR1B1—uterine cancer	6.88e-05	0.00617	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—AKR1B10—uterine cancer	6.81e-05	0.00611	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	6.76e-05	0.00607	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—AKR1B10—uterine cancer	6.75e-05	0.00605	CbGpPWpGaD
Bicalutamide—Feeling abnormal—Doxorubicin—uterine cancer	6.73e-05	0.000321	CcSEcCtD
Bicalutamide—Gastrointestinal pain—Doxorubicin—uterine cancer	6.68e-05	0.000318	CcSEcCtD
Bicalutamide—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.56e-05	0.00588	CbGpPWpGaD
Bicalutamide—Hypersensitivity—Epirubicin—uterine cancer	6.5e-05	0.00031	CcSEcCtD
Bicalutamide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	6.5e-05	0.00583	CbGpPWpGaD
Bicalutamide—Urticaria—Doxorubicin—uterine cancer	6.49e-05	0.000309	CcSEcCtD
Bicalutamide—CYP2D6—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.47e-05	0.00581	CbGpPWpGaD
Bicalutamide—Abdominal pain—Doxorubicin—uterine cancer	6.46e-05	0.000308	CcSEcCtD
Bicalutamide—Body temperature increased—Doxorubicin—uterine cancer	6.46e-05	0.000308	CcSEcCtD
Bicalutamide—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	6.42e-05	0.00576	CbGpPWpGaD
Bicalutamide—Asthenia—Epirubicin—uterine cancer	6.33e-05	0.000302	CcSEcCtD
Bicalutamide—CYP2D6—Metapathway biotransformation—AKR1B1—uterine cancer	6.33e-05	0.00568	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CXCL8—uterine cancer	6.31e-05	0.00566	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—AKR1B1—uterine cancer	6.27e-05	0.00563	CbGpPWpGaD
Bicalutamide—Pruritus—Epirubicin—uterine cancer	6.25e-05	0.000298	CcSEcCtD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	6.06e-05	0.00544	CbGpPWpGaD
Bicalutamide—Diarrhoea—Epirubicin—uterine cancer	6.04e-05	0.000288	CcSEcCtD
Bicalutamide—Hypersensitivity—Doxorubicin—uterine cancer	6.02e-05	0.000287	CcSEcCtD
Bicalutamide—Asthenia—Doxorubicin—uterine cancer	5.86e-05	0.000279	CcSEcCtD
Bicalutamide—Dizziness—Epirubicin—uterine cancer	5.84e-05	0.000278	CcSEcCtD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP11A1—uterine cancer	5.83e-05	0.00523	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—CTNNB1—uterine cancer	5.82e-05	0.00522	CbGpPWpGaD
Bicalutamide—CYP2C19—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.78e-05	0.00519	CbGpPWpGaD
Bicalutamide—Pruritus—Doxorubicin—uterine cancer	5.78e-05	0.000275	CcSEcCtD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP11A1—uterine cancer	5.75e-05	0.00516	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PHF1—uterine cancer	5.7e-05	0.00511	CbGpPWpGaD
Bicalutamide—Vomiting—Epirubicin—uterine cancer	5.61e-05	0.000267	CcSEcCtD
Bicalutamide—Diarrhoea—Doxorubicin—uterine cancer	5.59e-05	0.000266	CcSEcCtD
Bicalutamide—Rash—Epirubicin—uterine cancer	5.57e-05	0.000265	CcSEcCtD
Bicalutamide—Dermatitis—Epirubicin—uterine cancer	5.56e-05	0.000265	CcSEcCtD
Bicalutamide—Headache—Epirubicin—uterine cancer	5.53e-05	0.000263	CcSEcCtD
Bicalutamide—AR—Integrated Breast Cancer Pathway—ESR1—uterine cancer	5.45e-05	0.00489	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear beta catenin signaling and target gene transcription—EP300—uterine cancer	5.41e-05	0.00485	CbGpPWpGaD
Bicalutamide—Dizziness—Doxorubicin—uterine cancer	5.4e-05	0.000257	CcSEcCtD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—EP300—uterine cancer	5.36e-05	0.0048	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—CTNNB1—uterine cancer	5.34e-05	0.00479	CbGpPWpGaD
Bicalutamide—CYP2D6—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.32e-05	0.00477	CbGpPWpGaD
Bicalutamide—CYP3A4—Tryptophan metabolism—CYP19A1—uterine cancer	5.3e-05	0.00476	CbGpPWpGaD
Bicalutamide—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	5.27e-05	0.00473	CbGpPWpGaD
Bicalutamide—Nausea—Epirubicin—uterine cancer	5.24e-05	0.00025	CcSEcCtD
Bicalutamide—AR—Androgen receptor signaling pathway—PTEN—uterine cancer	5.21e-05	0.00467	CbGpPWpGaD
Bicalutamide—Vomiting—Doxorubicin—uterine cancer	5.19e-05	0.000247	CcSEcCtD
Bicalutamide—Rash—Doxorubicin—uterine cancer	5.15e-05	0.000245	CcSEcCtD
Bicalutamide—Dermatitis—Doxorubicin—uterine cancer	5.15e-05	0.000245	CcSEcCtD
Bicalutamide—Headache—Doxorubicin—uterine cancer	5.12e-05	0.000244	CcSEcCtD
Bicalutamide—CYP2C19—Metapathway biotransformation—AKR1C1—uterine cancer	5.05e-05	0.00453	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—EP300—uterine cancer	4.97e-05	0.00446	CbGpPWpGaD
Bicalutamide—Nausea—Doxorubicin—uterine cancer	4.85e-05	0.000231	CcSEcCtD
Bicalutamide—AR—Gene Expression—CHD4—uterine cancer	4.85e-05	0.00435	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CDH1—uterine cancer	4.74e-05	0.00425	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP11A1—uterine cancer	4.72e-05	0.00424	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—AKR1C1—uterine cancer	4.64e-05	0.00417	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—AKR1C1—uterine cancer	4.6e-05	0.00413	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	4.52e-05	0.00405	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1B10—uterine cancer	4.45e-05	0.00399	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—GPX3—uterine cancer	4.43e-05	0.00398	CbGpPWpGaD
Bicalutamide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—uterine cancer	4.29e-05	0.00385	CbGpPWpGaD
Bicalutamide—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—uterine cancer	4.23e-05	0.0038	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—PGR—uterine cancer	4.2e-05	0.00377	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP11A1—uterine cancer	4.17e-05	0.00374	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1B1—uterine cancer	4.14e-05	0.00371	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP11A1—uterine cancer	4.12e-05	0.00369	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—GPX3—uterine cancer	4.08e-05	0.00366	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SUZ12—uterine cancer	4.06e-05	0.00364	CbGpPWpGaD
Bicalutamide—AR—Coregulation of Androgen receptor activity—AKT1—uterine cancer	4.06e-05	0.00364	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—GPX3—uterine cancer	4.04e-05	0.00363	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—AKR1C3—uterine cancer	3.89e-05	0.00349	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP11A1—uterine cancer	3.84e-05	0.00344	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP11A1—uterine cancer	3.81e-05	0.00341	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP11A1—uterine cancer	3.79e-05	0.0034	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP11A1—uterine cancer	3.75e-05	0.00337	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.71e-05	0.00332	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ESR2—uterine cancer	3.7e-05	0.00332	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CXCL8—uterine cancer	3.7e-05	0.00332	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—AKR1C3—uterine cancer	3.58e-05	0.00321	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—AKR1C3—uterine cancer	3.54e-05	0.00318	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—CTNNB1—uterine cancer	3.5e-05	0.00314	CbGpPWpGaD
Bicalutamide—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—uterine cancer	3.48e-05	0.00312	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—PTEN—uterine cancer	3.41e-05	0.00306	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	3.41e-05	0.00306	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—SRD5A2—uterine cancer	3.38e-05	0.00303	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	3.32e-05	0.00297	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—EP300—uterine cancer	3.25e-05	0.00292	CbGpPWpGaD
Bicalutamide—AR—Regulation of nuclear SMAD2/3 signaling—AKT1—uterine cancer	3.24e-05	0.0029	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—EP300—uterine cancer	3.17e-05	0.00284	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—VEGFA—uterine cancer	3.08e-05	0.00276	CbGpPWpGaD
Bicalutamide—CYP2C19—Biological oxidations—CYP19A1—uterine cancer	3.07e-05	0.00275	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	3.07e-05	0.00275	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1C1—uterine cancer	3.04e-05	0.00272	CbGpPWpGaD
Bicalutamide—CYP2C19—Metapathway biotransformation—CYP19A1—uterine cancer	3.03e-05	0.00272	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—CDKN2B—uterine cancer	3.01e-05	0.0027	CbGpPWpGaD
Bicalutamide—AR—SIDS Susceptibility Pathways—VEGFA—uterine cancer	3e-05	0.00269	CbGpPWpGaD
Bicalutamide—AR—Androgen receptor signaling pathway—AKT1—uterine cancer	3e-05	0.00269	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	2.9e-05	0.0026	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	2.83e-05	0.00254	CbGpPWpGaD
Bicalutamide—CYP2D6—Biological oxidations—CYP19A1—uterine cancer	2.82e-05	0.00253	CbGpPWpGaD
Bicalutamide—CYP2C9—Biological oxidations—CYP19A1—uterine cancer	2.8e-05	0.00251	CbGpPWpGaD
Bicalutamide—CYP2D6—Metapathway biotransformation—CYP19A1—uterine cancer	2.79e-05	0.0025	CbGpPWpGaD
Bicalutamide—CYP2C9—Metapathway biotransformation—CYP19A1—uterine cancer	2.76e-05	0.00248	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—SMAD3—uterine cancer	2.75e-05	0.00247	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	2.7e-05	0.00242	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.68e-05	0.0024	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.68e-05	0.0024	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—GPX3—uterine cancer	2.67e-05	0.00239	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—KRAS—uterine cancer	2.62e-05	0.00235	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	2.55e-05	0.00229	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP11A1—uterine cancer	2.51e-05	0.00225	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP11A1—uterine cancer	2.48e-05	0.00222	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1B1—uterine cancer	2.44e-05	0.00219	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—STAR—uterine cancer	2.44e-05	0.00219	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—AKR1C3—uterine cancer	2.34e-05	0.0021	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—TP53—uterine cancer	2.33e-05	0.00209	CbGpPWpGaD
Bicalutamide—AR—Generic Transcription Pathway—ESR1—uterine cancer	2.24e-05	0.00201	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	2.17e-05	0.00195	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—PGR—uterine cancer	2.02e-05	0.00181	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.99e-05	0.00179	CbGpPWpGaD
Bicalutamide—AR—Integrated Breast Cancer Pathway—AKT1—uterine cancer	1.97e-05	0.00176	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.97e-05	0.00176	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.93e-05	0.00173	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—EZH2—uterine cancer	1.92e-05	0.00172	CbGpPWpGaD
Bicalutamide—CYP3A4—Biological oxidations—CYP19A1—uterine cancer	1.85e-05	0.00166	CbGpPWpGaD
Bicalutamide—CYP3A4—Metapathway biotransformation—CYP19A1—uterine cancer	1.82e-05	0.00163	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C1—uterine cancer	1.79e-05	0.00161	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ESR2—uterine cancer	1.78e-05	0.0016	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—SRD5A2—uterine cancer	1.65e-05	0.00148	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—NDUFB11—uterine cancer	1.65e-05	0.00148	CbGpPWpGaD
Bicalutamide—AR—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	1.63e-05	0.00146	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.6e-05	0.00144	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—SRD5A2—uterine cancer	1.52e-05	0.00136	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—NDUFB11—uterine cancer	1.52e-05	0.00136	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.51e-05	0.00136	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—NDUFB11—uterine cancer	1.5e-05	0.00135	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—SRD5A2—uterine cancer	1.5e-05	0.00135	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP11A1—uterine cancer	1.46e-05	0.00131	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—CDKN2B—uterine cancer	1.45e-05	0.0013	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—AKR1C3—uterine cancer	1.38e-05	0.00124	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—SMAD3—uterine cancer	1.32e-05	0.00119	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1B1—uterine cancer	1.19e-05	0.00107	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—STAR—uterine cancer	1.19e-05	0.00107	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.18e-05	0.00106	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1B1—uterine cancer	1.1e-05	0.000984	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—STAR—uterine cancer	1.1e-05	0.000984	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—STAR—uterine cancer	1.09e-05	0.000976	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1B1—uterine cancer	1.09e-05	0.000976	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—ESR1—uterine cancer	1.08e-05	0.000969	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—uterine cancer	1.08e-05	0.000965	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—SRD5A2—uterine cancer	9.92e-06	0.00089	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—NDUFB11—uterine cancer	9.92e-06	0.00089	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—POLD1—uterine cancer	9.36e-06	0.00084	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1C1—uterine cancer	8.76e-06	0.000785	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—POLD1—uterine cancer	8.61e-06	0.000772	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—POLD1—uterine cancer	8.54e-06	0.000766	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1C1—uterine cancer	8.05e-06	0.000722	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1C1—uterine cancer	7.98e-06	0.000716	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—RRM2—uterine cancer	7.8e-06	0.0007	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—DCN—uterine cancer	7.58e-06	0.00068	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—RRM2—uterine cancer	7.18e-06	0.000644	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—STAR—uterine cancer	7.17e-06	0.000644	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1B1—uterine cancer	7.17e-06	0.000644	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP11A1—uterine cancer	7.14e-06	0.00064	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—RRM2—uterine cancer	7.12e-06	0.000638	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—DCN—uterine cancer	6.97e-06	0.000625	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—DCN—uterine cancer	6.91e-06	0.00062	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKR1C3—uterine cancer	6.74e-06	0.000605	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP11A1—uterine cancer	6.57e-06	0.000589	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP11A1—uterine cancer	6.51e-06	0.000584	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKR1C3—uterine cancer	6.2e-06	0.000556	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKR1C3—uterine cancer	6.15e-06	0.000551	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—POLD1—uterine cancer	5.63e-06	0.000505	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1C1—uterine cancer	5.27e-06	0.000472	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—CYP19A1—uterine cancer	5.25e-06	0.000471	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—STK11—uterine cancer	5.25e-06	0.000471	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.93e-06	0.000442	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—STK11—uterine cancer	4.83e-06	0.000433	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—CYP19A1—uterine cancer	4.83e-06	0.000433	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—CYP19A1—uterine cancer	4.79e-06	0.00043	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—STK11—uterine cancer	4.79e-06	0.00043	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.7e-06	0.000422	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—RRM2—uterine cancer	4.69e-06	0.000421	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—DCN—uterine cancer	4.56e-06	0.000409	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—uterine cancer	4.49e-06	0.000403	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP11A1—uterine cancer	4.29e-06	0.000385	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—EP300—uterine cancer	4.29e-06	0.000385	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKR1C3—uterine cancer	4.05e-06	0.000364	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—MTHFR—uterine cancer	3.95e-06	0.000354	CbGpPWpGaD
Bicalutamide—AR—Gene Expression—AKT1—uterine cancer	3.9e-06	0.00035	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—MTHFR—uterine cancer	3.63e-06	0.000326	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—MTHFR—uterine cancer	3.6e-06	0.000323	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.48e-06	0.000312	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—uterine cancer	3.17e-06	0.000284	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—STK11—uterine cancer	3.16e-06	0.000283	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—CYP19A1—uterine cancer	3.16e-06	0.000283	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—MTHFR—uterine cancer	2.37e-06	0.000213	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PTEN—uterine cancer	2.2e-06	0.000197	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—EP300—uterine cancer	2.09e-06	0.000188	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PTEN—uterine cancer	2.02e-06	0.000181	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PTEN—uterine cancer	2e-06	0.00018	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—EP300—uterine cancer	1.93e-06	0.000173	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—EP300—uterine cancer	1.91e-06	0.000171	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—PIK3CA—uterine cancer	1.55e-06	0.000139	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—PIK3CA—uterine cancer	1.42e-06	0.000128	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—PIK3CA—uterine cancer	1.41e-06	0.000127	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PTEN—uterine cancer	1.32e-06	0.000118	CbGpPWpGaD
Bicalutamide—CYP2C19—Metabolism—AKT1—uterine cancer	1.27e-06	0.000113	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—EP300—uterine cancer	1.26e-06	0.000113	CbGpPWpGaD
Bicalutamide—CYP2D6—Metabolism—AKT1—uterine cancer	1.16e-06	0.000104	CbGpPWpGaD
Bicalutamide—CYP2C9—Metabolism—AKT1—uterine cancer	1.15e-06	0.000103	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—PIK3CA—uterine cancer	9.31e-07	8.35e-05	CbGpPWpGaD
Bicalutamide—CYP3A4—Metabolism—AKT1—uterine cancer	7.61e-07	6.83e-05	CbGpPWpGaD
